Biophytis Delays Annual Financial Statement Publication

Biophytis SA, a clinical-stage biotechnology company, has announced a delay in the release of its annual financial statements for the year ending December 31, 2025. The postponement is attributed to ongoing efforts surrounding a €2.015 million refinancing transaction, previously disclosed on March 11, 2026. This financial maneuver required significant attention from the company's resources to ensure successful execution.

Despite the initial deadline of April 30, 2026, statutory requirements and quality reviews necessitated by the refinancing have prompted Biophytis to defer the statement release. The company assures that all procedures will align with regulatory standards. Efforts are underway to publish the financial statements by the end of May 2026.